Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 3/20 | 0.46 |
| ▸ | PLAU | P00749 | 2/20 | 0.46 |
| ▸ | PLG | P00747 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | PLAT | P00750 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6792561 | 0.92 | ACACB (0.52) | ACACBCTSSF2PLAUPLG | |
| SCHEMBL6787163 | 0.89 | F10 (0.55) | ACACBF2PLAUPLGF10 | |
| SCHEMBL7407648 | 0.88 | ACACB (0.49) | ACACBCTSSF2PLAUPLG | |
| SCHEMBL6787527 | 0.82 | PLG (0.54) | CTSSF2PLAUPLGF10 | |
| SCHEMBL6792223 | 0.82 | TGM2 (0.52) | CTSSF2PLAUPLGF10 | |
| Hydrochloric Acid SCHEMBL6790131 | 0.81 | F2 (0.54) | CTSSF2PLAUPLGF10 | |
| SCHEMBL6786112 | 0.81 | PLG (0.51) | CTSSF2PLAUPLGF10 | |
| Hydrochloric Acid SCHEMBL6786786 | 0.79 | F2 (0.54) | CTSSF2PLAUPLGF10 | |
| SCHEMBL8548180 | 0.79 | F10 (0.49) | ACACBF2PLAUPLGF10 | |
| SCHEMBL6789447 | 0.78 | F10 (0.48) | CTSSF2PLAUPLGF10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6730672-B2 | PROTEASE INHIBITOR | ZENECA LIMITED (GB) | 2004-05-04 | — | — | US | disclosed |
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED | 2002-08-29 | — | — | US | disclosed |
| US-6225309-B1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | ZENECA LIMITED (GB) | 2001-05-01 | — | — | US | disclosed |
| US-5965559-A | STRONG INHIBITORY EFFECT AGAINST THE ACTIVATED COAGULATION PROTEASE KNOWN AS FACTOR XA; PREVENTION OF THE CLEAVAGE OF PROTHROMBIN TO THROMBIN; AMINO-SUBSTITUTED PYRIMIDINES AMIDINE GROUP-FREE | ZENECA LIMITED (GB) | 1999-10-12 | — | — | US | disclosed |
| EP-0783500-B1 | AMINOHETEROCYCLIC DERIVATIVES AS ANTITHROMBOTIC OR ANTICOAGULANT AGENTS | ZENECA LTD (GB) | 1998-07-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020119968-A1 | Aminoheterocyclic derivatives as antithrombotic or anticoagulant agents | SERPINC1, F2, SULT1E1 | ACACB 4066/4885CTSS 4403/4885F2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.